CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

I’ve been living with depression for almost 12 years. I’m 31 now and I found out I had major depressive disorder when I was 19. I had a miserable freshman year of college, but I didn't really ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) approved Johnson & Johnson’s ketamine-derived nasal spray to help millions of U.S.

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...